Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07005128 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
A Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT07005128: Recruiting Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
NCT07005128 is a Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 330 participants, above the 228-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07005128, a Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Durvalumab
- DRUG Tarlatamab
Study Locations (20)
California
- University of California Los Angeles - Santa Monica
- Presbyterian Intercommunity Hospital Health Whitter Hospital - Whittier
Minnesota
- Allina Health System dba Allina Health Cancer Institute - Minneapolis
- Mayo Clinic - Rochester
Tennessee
- Baptist Cancer Center - Memphis
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Texas
- US Oncology Research Investigational Products Center - Irving
- Texas Oncology Northeast Texas - Tyler
Buenos Aires
- Cemic - Ciudad Autonoma de Buenos Aires
- Hospital Universitario Austral - Pilar
Arkansas
- Saint Bernards Medical Center - Jonesboro
Connecticut
- Yale New Haven Hospital - New Haven
Illinois
- University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2029-07-15 |
| Phase | Phase 3 |
What NCT07005128 shows while recruiting
NCT07005128 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 228-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (45% higher).
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT07005128 names 20 study sites across 15 states, led by California, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07005128 about?
NCT07005128 is a clinical study titled "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)". The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
What is the current status of trial NCT07005128?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2025-08-18. Estimated completion is 2029-07-15.
What conditions does trial NCT07005128 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT07005128?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT07005128?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07005128 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07005128's enrollment target sits among peer trials
330 18th of 79 higher than 62 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI